Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies

By John Danesh, R. Collins, R. Peto. Circulation, 2000

984 citations recorded by the source corpus.

Subfields: Immunology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/4ca364e5748af1d80f853cf78224c3e1b50e4736

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. C. Iadecola
2. Alberico L. Catapano

In Pulmonary and Respiratory Medicine

1. C. Iadecola

In Surgery

1. Jan Boren
2. A. Tybjærg-Hansen
3. M. Chapman
4. Marja-Riitta Taskinen
5. G. Bakris
6. D. Nathan
7. C. Bushnell
8. M. S. Kirkman

Citations in the corpus

• Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2002, background): “In particular, apo B has been shown in prospective observational studies to be strongly associated with cardiovascular events (263).”
• Lipoprotein(a) as a cardiovascular risk factor: current status (2010, background): “9).(9) An updated meta-analysis of 31 prospective studies, involving a total of 9870 CHD cases, suggested that the corresponding combined risk was more modest (relative risk: 1.”
• Guidelines for the Primary Prevention of Stroke (2011, positive): “Lp(a) contributes to atherogenesis in experimental models(797) and is associated with an increased risk for coronary artery disease.(798,799) Apoprotein(a)”